Superstar Medical Holdings (02393) issued a profit warning. The net consolidated loss for the medium term is expected to be no less than 450,000 yuan in profit and loss year-on-year

Zhitongcaijing · 3d ago

According to Zhitong Finance App, Superstar Medical Holdings (02393) announced that compared with the Group's unaudited comprehensive net profit of approximately RMB 11.1 million for the six months ended June 30, 2025 (mid-term period of 2025), the Group is expected to earn an unaudited net consolidated loss of not less than RMB 450,000 for the six months ending June 30, 2026 (mid-term period 2026).

The Group is expected to switch from net profit to net loss in the mid-2026 period, mainly due to China's implementation of national and provincial drug collection plans to encourage dealers and service suppliers to directly purchase relevant medical products in large quantities from the National Health Security Administration at a lower competitive cost, putting downward pressure on pricing and leading to a decrease in the revenue of the medical products segment.